摘要
目的探讨血CA125水平对晚期卵巢癌患者新辅助化疗后理想肿瘤细胞减灭术的预测作用。方法回顾性分析2009年1月~2015年2月新诊断的晚期卵巢癌患者110例的临床资料,根据新辅助化疗后结果分为理想肿瘤细胞减灭术组(OCR组)及不理想细胞减灭术组(SCR组)。分析两组新辅助化疗前、后及手术后血CA125水平的变化,及其对理想手术成功率的预测作用。结果 OCR组及SCR组化疗前CA125分别为(1 466.1±682.4)、(1 628.2±738.7)U/m L,两组比较无统计学差异(t=1.196 4,P=1.117 1),而手术前两组CA125分别为(98.4±51.2)、(138.5±68.6)U/m L,有统计学差异(t=3.433 8,P=0.000 4),手术后尽管SCR组CA125水平(85.6±42.1)U/m L高于OCR组(78.1±36.3)U/m L,但两组比较无统计学意义(t=0.9363,P=0.1756)。术前CA125<100 U/m L者OCR组50例,占86.21%,而SCR组则为31例,占67.31%,两组比较有统计学意义(x^2=9.986 8,P=0.001 6)。铂类敏感及耐药患者手术前CA125≤35 U/m L者分别为24例和13例,各占38.10%和27.66%,而手术前CA125>35 U/m L者分别为39例和34例,分别各占61.90%和72.34%,两者比较无统计学差异(x^2=1.313 2,P=0.251 8)。铂类敏感及耐药患者手术前CA125下降≥80%者分别为52、26例,各占82.54%和55.32%,而手术前CA125下降<80%者分别为11、21例,各占17.46%和44.68%,两者比较有统计学差异(x^2=9.669 0,P=0.001 9)。结论以顺铂为基础的联合新辅助化疗用于晚期卵巢癌,可明显提高理想肿瘤细胞减灭术成功率,同时术前血CA125水平可在一定程度上预测理想肿瘤细胞减灭术成功率。
Objective To investigate the role of serum CA125 level in predicting optimal cystoreducive surgery for advanced ovarian cancer after neoadjuvant chemotherapy. Methods A retrospective analysis of clinical data of 110 patients with advanced ovarian cancer diagnosed in January 2009 to February 2015 was conducted. According to the results after neo- adjuvant chemotherapy, these patients were divided into optimal cytoreductive surgery group （ OCR group） and non - optimal cytoreductive surgery group （ SCR group）. Changes of Serum CA125 levels in two groups were analyzed before and after neo- adjuvant chemotherapy and after surgery. And the predicative function of success rates of optimal surgeries were also ana- lyzed. Results CA125 levels in the OCR group and SCR group before chemotherapy were （ 1 466. 1 ± 682.4 ） , （ 1 628.2 ±738.7） U / mL respectively, with no significant difference between the two groups （t = 1. 196 4, P = 1. 117 1 ）. Before sur- gery, CA125 levels in two groups were （98. 4 ±51.2）, （ 138.5 ±68.6） U / mL, respectively, showing statistically signifi- cant difference （t =3.433 8, P =0. 000 4）. Although CA125 level in SCR group was （85.6 ±42. 1 ） U / mL, higher than that in the OCR group （78. 1 ±36. 3） U / mL after surgery, there was no statistically significant difference （ t = 0. 936 3, P =0. 175 6）. Before surgery, there were 50 patients in OCR group with CA125 〈 100 U/mL, accounting for 86. 21% , while in the SCR group there were 31, accounting for 67.31% and there was statistically significant difference between the two groups （x2 = 9. 986 8, P = 0. 001 6）. Platinum -sensitive and resistant patients before surgery whose CA125 ≤35 U/mL were 24 cases and 13 cases, respectively in the two groups, accounting for 38.10% and 27.66%, respectively, while there were 39 and 34 patients with CA125 〉 35 U/mL, accounting for 61.90% and 72. 34% respectively. There was no significant difference between the two group （Z2 = 1. 313 2, P =0. 251 8）. The
出处
《现代医院》
2016年第5期650-652,共3页
Modern Hospitals
基金
唐山市科技局科技支撑项目(编号:No.111302097b)
